Autem Therapeutics is a privately held oncology therapeutic and bioelectric med-tech company headquartered in Hanover NH, USA that is developing a novel, non-invasive, and non-toxic pan-cancer treatment platform targeting hepatocellular carcinoma (HCC), glioblastoma (GBM) and other solid tumors. The company has received FDA breakthrough designation for its device for the treatment of advanced HCC patients. The AutEMsys device delivers personalized, amplitude-modulated electromagnetic frequencies (AM-EMF) and based on early clinical feasibility studies shows promise in shrinking cancerous tumors, enhancing quality of life, and extending survival in early and advanced stage cancer patient populations. Autem Therapeutics anticipates approval of FDA Investigational Device Exemptions (IDE) to initiate clinical trials in HCC and GBM in the second half of 2025.
Company Details
- Employees
- 14
- Founded
- -
- Address
- 35 S Main St, Hanover,new Hampshire 03755,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.autemtherapeutics.com
- Keywords
- bioelectric, HCC, solid tumours, quality of life, survival, medical device, electromagnetic frequencies (EM).
- HQ
- Hanover, New Hampshire
Autem Therapeutics Questions
Autem Therapeutics's website is http://www.autemtherapeutics.com
Autem Therapeutics's LinkedIn profile is https://www.linkedin.com/company/autem-therapeutics
Autem Therapeutics has
14 employees.
View email and phone details for 14
employees at Autem Therapeutics.
Autem Therapeutics's industry is
Biotechnology Research
Autem Therapeutics's top competitors are
Xeptiva Therapeutics,
Biomérieux,
Legend Biotech,
Panavance Therapeutics Inc.,
Kibow Biotech,
Multiplai Health,
Harmony Baby Nutrition,
Axenya,
Biomakers,
Viewmind Inc..
Autem Therapeutics's categories are Biotechnology Research
Autem Therapeutics's founding year is 2017
